Add BrightSurf on Google Email

American Society of Hematology


Over half of iron deficiency cases in large health system still unresolved at three years

A study of 13,084 adults with iron deficiency found that 42% had normal iron levels within three years, while 58% continued to have low ferritin levels. Factors associated with faster resolution included older age, male sex, and Medicare insurance. Persistent delays in treatment highlight the need for improved recognition and efficient...

SourceAmerican Society of Hematology·JournalBlood Advances·DateAug 15, 2024

MRI and lumbar puncture not necessarily required to manage CAR T-cell therapy complications

A new study suggests that magnetic resonance imaging (MRI) and lumbar puncture may not be necessary for diagnosing and managing immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy recipients. EEG findings often led to adjustments in medications, indicating its continued importance as a diagnostic tool.

SourceAmerican Society of Hematology·JournalBlood Advances·DateMar 19, 2024

Criteria for selecting who can enroll in multiple myeloma clinical trials may exclude patients from racial and ethnic minorities

A study found that clinical trial eligibility criteria may be a barrier to enrollment of patients from underrepresented racial and ethnic groups. Black patients were most likely to be deemed ineligible due to blood cell counts or lack of prior treatments, while Asian patients had the lowest rate of ineligibility.

New pain medications are still widely inaccessible to individuals living with sickle cell disease

A new study found that less than 4% of people with sickle cell disease have prescriptions for newer FDA-approved pain-relieving drugs, despite their availability. The study also revealed significant gaps in prescription patterns by geographic region and age group, emphasizing the need for education and access to treatment options.

SourceAmerican Society of Hematology·JournalBlood Advances·DateMar 8, 2023

CAR T-Cell therapy outcomes similar across different socioeconomic levels among pediatric patients with ALL

A new study finds no significant difference in overall survival or complete remission rates between children and young adults with different levels of poverty exposure, regardless of their neighborhood opportunity. CAR T-cell therapy is equally effective for those from disadvantaged households as it is for those from more socioeconomic...

Diversity is everyone’s responsibility: Researchers outline a path to representation in cancer clinical trials

Researchers outline a five-step approach to increase racial representation in cancer clinical trials through DRIVE: Diversity officer, Ranking of clinical studies, Individual diversity plan, Verification, and Training. This can lead to more inclusive and individualized treatment for diverse patient populations.

SourceAmerican Society of Hematology·JournalBlood Advances·DateAug 25, 2022

Young Black patients with AML face significantly worse outcomes than white patients of the same age

A new study published in Blood Advances highlights significant inequities in diagnosis, treatment, and care between Black and white patients with acute myeloid leukemia (AML). Young adult Black patients were five times more likely to die within 30 days of beginning treatment compared to comparable white patients. The study also found c...

SourceAmerican Society of Hematology·JournalBlood Advances·DateJul 5, 2022

The cost of living with sickle cell disease

A new study reveals that individuals with sickle cell disease spend approximately $1.7 million on lifetime medical expenses, highlighting the significant economic burden of living with this disease. The study found that out-of-pocket costs for those with private insurance plans can be as high as 5-10% of their annual income.

SourceAmerican Society of Hematology·JournalBlood Advances·DateMay 16, 2022

Study shines light on fertility education gaps among adolescent and young adult men with sickle cell disease

A new study found that many adolescent and young adult men with sickle cell disease are unaware of potential fertility issues associated with the disorder. The research suggests a need for accessible fertility education and testing options to address this knowledge gap, particularly in how SCD and treatments may affect fertility.

SourceAmerican Society of Hematology·JournalBlood Advances·DateApr 20, 2022